Hippo Pathway Inhibition for Chronic Nephropathy Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment for chronic nephropathies such as nephronophthisis, which leads to end-stage kidney disease, due to uncharacterized dysregulated pathways causing kidney degeneration.
Innovation Solution
Administering inhibitors of the Hippo signaling pathway to patients with chronic nephropathies to reduce inflammation and fibrosis by inhibiting the expression and secretion of pro-inflammatory cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered for nephronophthisis, then the disease progresses to end-stage kidney disease, but administering conventional therapies does not effectively halt progression due to uncharacterized dysregulated pathways
Solution Approach 1:
The invention changes the therapeutic parameter from conventional approaches to specifically targeting the Hippo signaling pathway. By identifying and inhibiting this specific pathway (MST1/2-LATS1/2-YAP/TAZ axis), the treatment effectively addresses the dysregulated pathways causing kidney degeneration in nephronophthisis, transforming the approach from general supportive care to targeted molecular therapy.
2Object-affected harmful factors
If the Hippo signaling pathway is inhibited, then inflammation and fibrosis are reduced, but the complexity of the treatment mechanism increases due to targeting a specific molecular pathway
Solution Approach 1:
The invention extracts and isolates the specific Hippo signaling pathway (MST1/2-LATS1/2-YAP/TAZ axis) from the complex network of cellular signaling pathways. By focusing treatment on this specific extracted pathway rather than attempting to modulate the entire signaling network, the invention reduces inflammation and fibrosis through targeted inhibition while providing a clear mechanistic understanding.
3Object-generated harmful factors
If YAP inhibition is used as a therapeutic strategy, then renal inflammation may be restricted, but previous studies suggest this approach is not valid for NPH as LKB1 and YAP are parallel negative regulators of an uncharacterized pathway
Solution Approach 1:
Instead of directly inhibiting YAP as previously attempted, the invention inverts the approach by targeting the upstream regulators (MST1/2 and LATS1/2 kinases) that normally phosphorylate and inhibit YAP. By activating the Hippo pathway through upstream inhibition rather than direct YAP suppression, the treatment achieves therapeutic effect while avoiding the limitations of parallel negative regulation identified in previous studies.
Data Source
AI summary
Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.